Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
177Lu-anti-CD19 antibody is a preclinical-stage therapeutic radiopharmaceutical consisting of a monoclonal antibody targeting B-lymphocyte antigen CD19 conjugated to the beta-emitting radioisotope lutetium-177 (177Lu). Developed by researchers at Changping Laboratory and Peking University, the agent is designed to achieve 'immune resetting' in autoimmune diseases such as systemic lupus erythematosus (SLE). By binding to CD19-expressing B cells and plasma cells, the radiopharmaceutical delivers localized cytotoxic radiation, leading to profound and sustained B-cell depletion and a subsequent reduction in pathogenic autoantibody levels. In preclinical mouse models of SLE, a single dose of 177Lu-anti-CD19 antibody significantly extended survival, improved skin lesions and lupus nephritis, and demonstrated therapeutic efficacy.
| Indication | Highest phase | Status |
|---|---|---|
| systemic lupus erythematosus-associated nephritis (lupus nephritis) | Preclinical | Active |
Every indication, with countries and timelines, is in the full profile.
| Market | Status | Year |
|---|---|---|
| United States | Not approved | — |
| European Union | Not approved | — |
| China | Not approved | — |
| Japan | Not approved | — |
Approved indications and other markets are in the full profile.
Patent families, expiry dates and exclusivities are in the full profile.
Lead indication: systemic lupus erythematosus-associated nephritis (lupus nephritis)
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 177Lu-anti-CD19 antibody.
Work on 177Lu-anti-CD19 antibody? Claim this page to correct or add information. Claim this page